XARELTO®: Dosing in initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Once-daily treatment after 21 days of twice-daily dosing

No dose adjustment based on weight

15 mg

For the first 21 days, twice daily with food, at the same time each day in patients with CrCl 15 mL/min

20 mg

Starting at day 22, once daily with food, at the same time each day for remaining treatment in patients with CrCl 15 mL/min

15 mg

For the first 21 days, twice daily with food, at the same time each day in patients with CrCl 15 mL/min

20 mg

Starting at day 22, once daily with food, at the same time each day for remaining treatment in patients with CrCl 15 mL/min

Renal Dose Consideration*

  • Avoid using XARELTO® in patients with CrCl <15 mL/min

30-day Starter Pack for patients with DVT/PE

Image of XARELTO® packaging with starter dosageImage of XARELTO® packaging with starter dosage

*Calculate CrCl based on actual weight.

Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).

The decision regarding initiation setting should be based on the prescriber's clinical judgment.

CrCl = creatinine clearance; DVT = deep vein thrombosis; PE = pulmonary embolism.